Filing Details

Accession Number:
0001415889-24-016416
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-06-11 18:00:05
Reporting Period:
2024-06-08
Accepted Time:
2024-06-11 18:00:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070494 Acadia Pharmaceuticals Inc ACAD Pharmaceutical Preparations (2834) 061376651
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1899977 C. Mark Schneyer C/O Acadia Pharmaceuticals Inc.
12830 El Camino Real, Suite 400
San Diego CA 92130
Evp, Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-06-08 1,893 $0.00 35,539 No 4 M Direct
Common Stock Disposition 2024-06-10 975 $14.79 34,564 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2024-06-08 1,893 $0.00 1,893 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
  2. Includes 1,593 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2024.
  3. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.675 to $14.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  5. The restricted stock units vest in three equal annual installments on each of June 8, 2022, June 8, 2023 and June 8, 2024.